IRIS
DI BIAGIO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.308
AS - Asia 5.311
NA - Nord America 4.705
Continente sconosciuto - Info sul continente non disponibili 1.045
SA - Sud America 438
AF - Africa 118
OC - Oceania 5
Totale 45.930
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 33.455
US - Stati Uniti d'America 4.345
SG - Singapore 1.924
CN - Cina 1.283
VN - Vietnam 872
BD - Bangladesh 720
FR - Francia 348
BR - Brasile 255
HK - Hong Kong 156
CA - Canada 151
FI - Finlandia 127
DE - Germania 91
MX - Messico 76
AR - Argentina 73
GB - Regno Unito 68
JP - Giappone 50
IN - India 44
IQ - Iraq 42
NL - Olanda 39
ID - Indonesia 34
JM - Giamaica 28
ZA - Sudafrica 28
CH - Svizzera 25
PH - Filippine 25
CL - Cile 23
EC - Ecuador 22
PK - Pakistan 21
TR - Turchia 20
CO - Colombia 19
ES - Italia 19
VE - Venezuela 18
CR - Costa Rica 17
IE - Irlanda 16
RU - Federazione Russa 16
TN - Tunisia 15
UA - Ucraina 15
ET - Etiopia 14
GT - Guatemala 14
MA - Marocco 14
SA - Arabia Saudita 14
TH - Thailandia 13
TT - Trinidad e Tobago 13
UZ - Uzbekistan 13
NI - Nicaragua 12
NP - Nepal 11
PE - Perù 11
DZ - Algeria 10
HN - Honduras 10
MY - Malesia 10
PY - Paraguay 10
PL - Polonia 9
KE - Kenya 8
SE - Svezia 8
JO - Giordania 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
BB - Barbados 6
BE - Belgio 6
SV - El Salvador 6
AT - Austria 5
AU - Australia 5
DO - Repubblica Dominicana 5
EG - Egitto 5
LT - Lituania 5
MD - Moldavia 5
NG - Nigeria 5
RS - Serbia 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
CZ - Repubblica Ceca 4
KR - Corea 4
KZ - Kazakistan 4
PR - Porto Rico 4
PS - Palestinian Territory 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
AZ - Azerbaigian 3
BG - Bulgaria 3
BH - Bahrain 3
BS - Bahamas 3
DK - Danimarca 3
GA - Gabon 3
GR - Grecia 3
HR - Croazia 3
HU - Ungheria 3
IL - Israele 3
LB - Libano 3
MT - Malta 3
NO - Norvegia 3
SI - Slovenia 3
AG - Antigua e Barbuda 2
CU - Cuba 2
GH - Ghana 2
IR - Iran 2
KG - Kirghizistan 2
LV - Lettonia 2
MK - Macedonia 2
PA - Panama 2
SC - Seychelles 2
Totale 44.853
Salva come PNG Salva come JPEG
Città #
Genova 16.241
Genoa 10.625
Rapallo 2.896
Vado Ligure 2.872
San Jose 1.007
Singapore 857
Ashburn 574
Lauterbourg 311
Ho Chi Minh City 256
Beijing 253
Hanoi 218
New York 218
Council Bluffs 207
Hong Kong 147
Helsinki 117
Santa Clara 105
Los Angeles 96
Bordighera 89
Milan 71
Rome 70
Frankfurt am Main 68
Chicago 57
Buffalo 55
Haiphong 54
St Louis 52
Mexico City 46
Tokyo 43
Atlanta 41
Boardman 40
Naples 38
Dallas 37
Da Nang 32
São Paulo 30
Houston 29
Orem 29
Turin 29
Tianjin 28
Toronto 28
Florence 25
Las Vegas 24
Philadelphia 24
Biên Hòa 22
Phoenix 22
Brooklyn 20
Palermo 19
Zurich 19
Montreal 18
Baghdad 17
Dhaka 17
Washington 17
Bologna 16
City of London 16
Amsterdam 15
Dublin 15
Kingston 15
London 15
Rio de Janeiro 15
Miami 14
The Bronx 14
Bari 13
Hải Dương 13
Louisville 13
Shanghai 13
Charlotte 12
Des Moines 12
Guangzhou 12
Guatemala City 12
San José 12
Bắc Ninh 11
Managua 11
Jacksonville 10
Jakarta 10
Johannesburg 10
Santiago 10
Tashkent 10
Addis Ababa 9
Cardiff 9
Denver 9
Kyiv 9
Lappeenranta 9
Lima 9
Milwaukee 9
Nuremberg 9
Paris 9
Queens 9
San Antonio 9
Tunis 9
Verona 9
Catania 8
Istanbul 8
Kansas City 8
Marseille 8
Memphis 8
New Orleans 8
Newark 8
Ninh Bình 8
Novara 8
Raleigh 8
San Juan 8
Seattle 8
Totale 38.742
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 344
CD8+CD28-CD127loCD39+regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection? 269
The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials 249
Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc 246
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. 234
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 230
Inflammation markers correlate with common carotid intima-media thickness in patients perinatally infected with human immunodeficiency virus 1. 229
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: A multicenter regional simulation 229
Bloodstream infections in patients living with HIV in the modern cART era 229
Quality of Life Among Hiv Patients: Results from the Ianua Clinical Trial 228
A tool for the evaluation of the cost effectiveness of AIDS therapies 226
Is it still worthwhile to perform quarterly CD4+ T lymphocyte cell counts on HIV-1 infected stable patients? 225
Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. 223
Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system 223
A Standard Interface for Data Reuse in Infectious Diseases 223
La vaccinazione nel paziente con infezione da HIV: attuali raccomandazioni e strategie multidisciplinari per il raggiungimento dei soggetti suscettibili. L’esperienza della Liguria 214
Budget Impact Analysis of Sofosbuvir-Based Regimens for The Treatment of Hiv/Hcv Co-Infected Patients In Northern Italy: The Liguria Region Simulation 211
'Emergency exit' of bone-marrow-resident CD34+ DNAM-1 bright CXCR4+-committed lymphoid precursors during chronic infection and inflammation 206
Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. Study-Investigation on Antiretroviral Therapy) 202
A comparison of inpatient admissions in 2012 from two European countries 201
Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. 200
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impact 198
Use of maraviroc in clinical practice: a multicenter observational study 198
Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis 197
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 197
Cost per care of the first year of direct antiviral agents in the liguria region: A multicenter analysis 196
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy 196
Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study 194
Ricoveri ospedalieri dei pazienti con infezione da HIV in Liguria: risultati preliminari dello studio ACTEA 193
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 193
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 192
Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy 191
Disseminated histoplasmosis with mucocutaneous immune reconstitution inflammatory syndrome in an HIV-infected patient 188
Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts 188
Rete Ligure dell’HIV: due anni di esperienza nella gestione del dato clinico 187
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine reverse transcription inhibitor backbone 182
Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. 182
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?”. 182
Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study 182
Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection 181
Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course 180
Bloodstream infections in critically ill patients with COVID-19 180
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 177
Predictors of retention in care for HIV-infected patients: data from San Martino Hospital cohort in Genoa 177
Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells 177
Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy 176
Reducing CD4+ lymphocyte cell monitoring in HIV-1 stable patients: a forecast of the cost saving 173
Bedaquiline: A new hope for shorter and better anti-tuberculosis regimens 173
Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA < 50 cp/mL 173
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir 172
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 172
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 168
Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. 166
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. 166
How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy 166
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 165
Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection. 163
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 163
The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients. 162
Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1-Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. 162
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature 162
Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy 161
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 160
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 159
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 159
How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis 159
Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children 158
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 158
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 158
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. 157
Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response 157
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 157
Architettura, Design e Visualità 156
Clinically stable treatment-experienced adults receiving tenofovir and didanosine. 156
A comprehensive development agenda on tenofovir alafenamide in clinical practice 155
Ibalizumab and fostemsavir in the management of heavily pre-treated HIV-infected patients 155
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 154
IANUA: a regional project for the determination of costs in HIV-infected patients 154
From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care 153
Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome 153
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 153
Correction to: Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy (Infection, 10.1007/s15010-017-1063-7) 152
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 150
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area 150
Infectious Complications of Cancer Chemotherapy in HIV Patients 149
Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years 149
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 149
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 149
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 148
Assessment of appropriateness of first-line combined antiretroviral treatment (cART): the preliminary results of Liguria experience V.E.L.A. study 148
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 148
Efficacy and safety of darunavir and etravirine in an antiretroviral multiexperienced youth with vertically HIV-1 infection 148
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? 148
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 148
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration 146
LiHlm-Web: a web-application in order to collect, share and analyze immunological data of HIV patients in multicentric studies 146
Cost assessment of haart: the ianua clinical trial in Genoa 146
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 146
Factors associated with hospital admission for COVID-19 in HIV patients 146
La conta dei linfociti nel monitoraggio del paziente con infezione da HIV: evidenze per un impiego ragionato 145
Totale 17.974
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.362
article - articoli 154.311
book - libri 113
conference - conferenze 8.045
curatela - curatele 713
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.180
Totale 332.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.461 134 151 124 378 133 278 192 798 342 380 132 419
2022/20233.611 359 324 37 351 465 482 80 250 555 179 456 73
2023/20242.314 116 220 51 293 187 350 160 141 119 79 220 378
2024/20257.370 166 543 186 448 1.010 795 841 1.137 292 384 676 892
2025/202614.385 1.513 374 941 878 1.704 1.138 2.102 724 1.042 1.501 1.205 1.263
2026/20271.310 1.310 0 0 0 0 0 0 0 0 0 0 0
Totale 45.930